Fact-checked by Grok 2 weeks ago

Histamine intolerance

Histamine intolerance is a proposed metabolic disorder characterized by the body's reduced ability to break down histamine, leading to its accumulation and symptoms that mimic allergic reactions but are not mediated by immunoglobulin E (IgE). It is primarily attributed to diminished activity of the enzyme diamine oxidase (DAO), which degrades dietary histamine in the gastrointestinal tract, often due to genetic factors, medications, or underlying conditions. However, the condition remains controversial, with recent research questioning its existence as a distinct entity and the reliability of diagnostic tests.^[1]^[2]^[3]^[4]

Fundamentals

Definition and Classification

Histamine intolerance is a presumed non-immune-mediated disorder involving adverse reactions to dietary histamine, resulting from an impaired capacity to degrade ingested histamine, which leads to its accumulation and the development of symptoms resembling those of allergic responses.^[2] This condition arises when the body's histamine-metabolizing enzymes, particularly in the gastrointestinal tract, fail to sufficiently break down histamine from food sources, causing a disequilibrium between histamine intake and elimination.^[5] Histamine, a biogenic amine involved in various physiological processes, becomes problematic in this context due to its accumulation rather than an immune-mediated release.^[1] Classified as a pseudoallergy or enteral histaminosis, histamine intolerance is distinguished from immunological hypersensitivities and is not recognized as a distinct diagnostic entity in the International Classification of Diseases (ICD-11).^[6] Medical authorities often refer to it more broadly as "adverse reactions to ingested histamine" to reflect its metabolic rather than allergic basis, emphasizing its status as a form of food intolerance rather than a true allergy.^[7] The concept has roots in early observations of histamine-related food reactions dating back to the mid-20th century, but it was more formally described in scientific literature starting in the 1990s, with a seminal review in 2007 highlighting its mechanisms and clinical implications.^[5] Recognition grew significantly in the 2010s, driven by patient reports and preliminary clinical studies exploring its prevalence and management.^[2] In contrast to true food allergies, which involve IgE-mediated immune activation and can lead to severe anaphylaxis, histamine intolerance lacks an immunological component and primarily affects susceptible individuals through direct pharmacological effects of excess histamine.^[1] It also differs from other common intolerances, such as lactose intolerance, where symptoms stem from the undigested fermentation of a specific carbohydrate due to enzyme deficiency, whereas histamine intolerance specifically pertains to the overload of a biogenic amine in the system.^[4] This differentiation underscores the metabolic focus of histamine intolerance within the broader spectrum of adverse food reactions.

Histamine Physiology

Histamine is a biogenic amine derived from the amino acid L-histidine through decarboxylation catalyzed by the enzyme L-histidine decarboxylase (HDC), which requires pyridoxal-5'-phosphate as a cofactor.^[8] This synthesis primarily occurs in specific cells such as mast cells, basophils, enterochromaffin-like cells in the gastric mucosa, and neurons.^[8] Endogenously, histamine is produced and stored in granules within mast cells and basophils, from where it is released in response to stimuli like allergens or injury; additional endogenous sources include macrophages, neutrophils, and the gastrointestinal microbiota, such as certain strains of Lactobacillus reuteri and Escherichia coli.^[8]^[9] Exogenous histamine enters the body mainly through the diet, particularly from fermented or aged foods where bacterial decarboxylation of histidine occurs, including examples like cheese, wine, and sauerkraut.^[2] In normal physiology, histamine exerts diverse effects through four G-protein-coupled receptors (H1R, H2R, H3R, and H4R) distributed across various tissues.^[9] Activation of H1 receptors on endothelial and smooth muscle cells promotes vasodilation and increased vascular permeability, key components of the immune response that facilitate immune cell recruitment during inflammation or allergic reactions.^[8] H2 receptors, primarily on gastric parietal cells, stimulate hydrochloric acid secretion to aid digestion, while also modulating immune functions such as enhancing regulatory T-cell activity and interleukin-10 production to dampen excessive inflammation.^[8]^[9] In the central nervous system, H3 receptors act as autoreceptors to regulate histamine release and modulate neurotransmission by inhibiting the release of other neurotransmitters like dopamine, serotonin, and acetylcholine; H4 receptors, expressed on immune cells such as eosinophils and mast cells, influence chemotaxis, cytokine production, and Th2/Th17 immune responses, contributing to inflammation modulation.^[8]^[9] Histamine metabolism maintains physiological balance through two primary enzymatic pathways. Extracellular degradation occurs via diamine oxidase (DAO), which is highly active in the intestinal mucosa, kidneys, and placenta, oxidizing histamine to imidazole acetaldehyde before further breakdown.^[8] Intracellularly, histamine N-methyltransferase (HNMT) predominates in tissues like the central nervous system, liver, and bronchial epithelium, methylating histamine to N-methylhistamine, which is then oxidized by monoamine oxidase.^[8] These pathways collectively metabolize over 97% of histamine, with only 2-3% excreted unchanged in urine, ensuring that synthesis, release, and degradation remain in equilibrium to prevent accumulation under normal conditions.^[8] This homeostasis is crucial for histamine's role as a signaling molecule without causing adverse effects.^[9]

Pathophysiology

Etiology and Causes

Histamine intolerance primarily arises from impaired degradation of histamine due to reduced activity of the enzymes diamine oxidase (DAO) and histamine N-methyltransferase (HNMT). DAO, encoded by the AOC1 gene, is the principal enzyme responsible for breaking down extracellular histamine in the intestines, while HNMT, encoded by the HNMT gene, handles intracellular histamine metabolism primarily in the liver and other tissues. Deficiencies in these enzymes lead to histamine accumulation, triggering intolerance symptoms when dietary or endogenous histamine exceeds the body's capacity to metabolize it.^[2] Genetic polymorphisms in the AOC1 gene are a key primary cause, with variants such as rs10156191 (p.Thr16Met), rs1049742 (p.Ser332Phe), and rs1049793 (p.His664Asp) associated with significantly reduced DAO activity—often by 20-50% in heterozygous carriers. These polymorphisms are common in the general population, conferring a predisposition to histamine intolerance, particularly when combined with environmental triggers. Similarly, variants in the HNMT gene, such as rs1050891 (p.Thr105Ile), impair methylation-based histamine breakdown and have been linked to altered histamine levels in allergic conditions, though their prevalence in histamine intolerance specifically is lower and less well-quantified. DAO deficiency linked to AOC1 variants exhibits autosomal inheritance patterns, with homozygous carriers showing more severe reductions in enzyme function, increasing familial risk through genetic predisposition and family history of related sensitivities.^[2]^[10]^[2] Acquired factors further contribute by suppressing DAO production or activity. Gut dysbiosis, including conditions like small intestinal bacterial overgrowth (SIBO), disrupts the intestinal mucosa and reduces DAO expression; studies from 2022 identified lower levels of beneficial bacteria (e.g., Faecalibacterium prausnitzii) and higher histamine-producing species (e.g., Enterobacteriaceae, Enterococcus faecalis) in affected individuals, linking microbiome alterations to DAO suppression. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs like naproxen), certain antibiotics (e.g., clavulanic acid), and proton pump inhibitors (PPIs) inhibit DAO either directly or by damaging the gut lining, exacerbating intolerance in susceptible individuals. Alcohol inhibits DAO by competing for aldehyde dehydrogenase and increasing gut permeability, while estrogen fluctuations—observed during menstruation, pregnancy, or menopause—can lower DAO activity due to hormonal modulation of enzyme expression.^[11]^[2]^[12] Other contributors include chronic inflammation, which downregulates DAO through mucosal damage in conditions like inflammatory bowel disease, and dysfunction in the liver or kidneys, where DAO and HNMT are prominently expressed—renal impairment, for instance, elevates plasma histamine by reducing clearance. A high-histamine diet does not cause intolerance but amplifies underlying vulnerabilities by overwhelming compromised degradation pathways. Overall, histamine intolerance lacks a single etiology, representing a multifactorial interplay of genetic, microbial, pharmacological, and physiological factors, with recent evidence (2020-2024) emphasizing microbiome-driven DAO suppression as a modifiable contributor.^[2]^[2]

Biochemical Mechanisms

Histamine intolerance arises primarily from impaired degradation of histamine, the key enzymes being diamine oxidase (DAO) and histamine N-methyltransferase (HNMT). DAO, predominantly expressed in the intestinal mucosa, catalyzes the oxidative deamination of dietary histamine into inactive metabolites, preventing its absorption into the bloodstream. When DAO activity is reduced, ingested histamine bypasses this barrier, enters systemic circulation, and accumulates, exacerbating intolerance. Similarly, HNMT, an intracellular enzyme abundant in bronchial epithelium and vascular endothelium, methylates histamine for further breakdown; reduced HNMT function contributes to prolonged histamine presence in tissues. This dual enzymatic deficiency disrupts the balance between histamine intake and clearance, leading to elevated levels that trigger physiological responses.^[2] The accumulated histamine exerts effects by binding to four G-protein-coupled receptors (H1R, H2R, H3R, H4R) distributed across various tissues. Activation of H1 receptors on endothelial cells and smooth muscle promotes vasodilation, increased vascular permeability, and pruritus through phospholipase C-mediated signaling. H2 receptor stimulation in gastric parietal cells enhances acid secretion via cyclic AMP pathways, potentially contributing to gastrointestinal disturbances. H3 receptors, primarily presynaptic in the central and peripheral nervous systems, modulate neurotransmitter release, influencing neurological symptoms, while H4 receptors on immune cells like eosinophils and mast cells amplify inflammatory cascades. These receptor interactions underlie the pseudo-allergic manifestations of histamine intolerance, distinct from IgE-mediated responses.^[2] Symptoms manifest when circulating histamine exceeds an individual's tolerance threshold, which varies based on residual enzyme capacity. This threshold concept reflects a dose-response relationship where low-level exposure may be tolerated, but cumulative intake from high-histamine foods overwhelms degradation, leading to systemic overload. Certain foods, such as strawberries, act as histamine liberators by prompting endogenous release from mast cells, compounding the exogenous load and lowering the effective threshold. Qualitatively, this interaction follows a non-linear dose-response, where even moderate liberator intake can precipitate effects in enzyme-deficient individuals.^[13]^[2] Recent evidence supports these mechanisms, with studies from 2021 to 2025 demonstrating elevated plasma histamine levels in histamine-intolerant patients following histamine-rich meals, correlating with low DAO activity. For instance, oral provocation tests show postprandial histamine spikes up to threefold higher in affected individuals compared to controls. Supplementation with exogenous DAO has been shown to normalize these elevations by enhancing gut degradation in clinical trials. These findings underscore the biochemical pathway's role in symptom provocation and validate targeted interventions.^[14]^[15]^[16]

Clinical Aspects

Signs and Symptoms

Symptoms of histamine intolerance typically manifest shortly after the ingestion of histamine-rich foods, often within minutes to hours, and can persist for several hours to days depending on the exposure level and individual factors. These symptoms are dose-dependent, meaning their severity correlates with the amount of histamine consumed, and they may become chronic if the condition remains untreated. In severe cases, recent reports from 2024 and 2025 have highlighted increased recognition of anaphylaxis-like episodes, such as recurrent swelling, hypotension, and respiratory distress mimicking true anaphylaxis.^[1]^[2]^[17] Gastrointestinal symptoms are the most prevalent, affecting approximately 70-80% of individuals with histamine intolerance, and include abdominal pain, bloating, diarrhea, nausea, and constipation. Bloating is particularly common, reported in up to 92% of cases, while abdominal pain occurs in about 68% and diarrhea in 71%. These manifestations often arise postprandially and contribute significantly to the discomfort experienced.^[1]^[18] Dermatological symptoms encompass flushing, hives (urticaria), itching (pruritus), and flares of eczema or dermatitis, which can appear as redness, rash, or swelling on the skin. These reactions are frequently among the first noticeable signs following histamine exposure.^[1]^[2] Respiratory symptoms involve rhinitis, nasal congestion, rhinorrhea, sneezing, cough, and asthma-like wheezing or dyspnea, potentially leading to difficulty breathing in more pronounced cases.^[1]^[2] Neurological symptoms commonly include headaches (affecting about 65% of patients), migraines, dizziness, anxiety, and fatigue, which may exacerbate overall malaise.^[1]^[2] Cardiovascular symptoms feature hypotension, tachycardia, palpitations, and in severe instances, collapse, with dizziness reported in 66% and palpitations in 47% of cases.^[1] Other symptoms may include menstrual irregularities or cramps in women. Notably, symptoms are reversible and often resolve within 4-8 weeks following adherence to a low-histamine elimination diet.^[1]^[2]

Diagnosis

Diagnosing histamine intolerance (HIT) begins with a detailed clinical history, focusing on the temporal association between symptom onset and consumption of high-histamine foods such as aged cheeses, fermented products, or alcohol.^[1] Patients are encouraged to maintain symptom diaries to document dietary triggers, symptom severity, and patterns, which help identify correlations with histamine-rich meals and distinguish HIT from other conditions.^[19] This approach is essential due to the nonspecific nature of symptoms, which can mimic various disorders. A key diagnostic tool is the elimination diet trial, involving a 2-4 week low-histamine diet that restricts foods high in histamine or histamine liberators, followed by controlled reintroduction to provoke symptoms.^[1] A positive response, characterized by symptom resolution during elimination and recurrence upon reintroduction, strongly supports the diagnosis of HIT.^[14] A 2025 study proposes characterizing the spectrum of HIT by specific symptom patterns, frequencies, timelines, and stages to improve diagnosis.^[20] Laboratory tests provide supportive evidence but lack standardization. Serum diamine oxidase (DAO) activity, measured via enzyme-linked immunosorbent assay (ELISA), is suggestive of HIT when levels are below 10 U/mL, indicating impaired histamine degradation.^[21] Plasma histamine levels, assessed post-challenge or during symptoms, may be elevated above 1 ng/mL in affected individuals, though normal ranges vary (typically ≤1.8 ng/mL).^[22] Serum tryptase testing is recommended to assess for mast cell disorders. A baseline level >20 ng/mL suggests clonal disorders like systemic mastocytosis, while an acute rise (>120% + 2 ng/mL above baseline) during symptoms supports MCAS. Normal levels help differentiate from these but do not fully exclude MCAS.^[23]^[24] Genetic testing for polymorphisms in the AOC1 (encoding DAO) and HNMT (histamine N-methyltransferase) genes is commercially available and can identify predispositions to reduced enzyme function, such as specific single-nucleotide polymorphisms (SNPs) in AOC1.^[2] However, these variants are not diagnostic in isolation, as they must be interpreted alongside clinical and dietary findings. There is no gold standard for HIT diagnosis, and challenges include significant symptom overlap with irritable bowel syndrome (IBS), MCAS, and food allergies, leading to frequent misdiagnosis.^[25] Recent guidelines from 2023 emphasize multidisciplinary evaluation involving allergists, gastroenterologists, and dietitians to address these complexities.^[25] Differential diagnosis requires excluding mimics through targeted testing: skin prick or serum IgE tests to rule out true allergies (typically negative in HIT), and gastrointestinal endoscopy or colonoscopy to investigate structural issues in suspected IBS or other enteric disorders.^[1]

Management

Treatment Strategies

Treatment of histamine intolerance primarily involves symptomatic management through pharmacological and supplemental interventions aimed at blocking histamine effects, enhancing its degradation, or preventing its release from mast cells. Antihistamines, including H1 receptor blockers such as loratadine for dermatological and respiratory symptoms, and H2 receptor blockers like famotidine for gastrointestinal issues, are used on a short-term basis to alleviate acute symptoms.^[1] These agents provide relief by competitively inhibiting histamine binding to receptors, though their long-term use is limited due to potential interference with diamine oxidase (DAO) activity, the primary enzyme responsible for histamine breakdown.^[1] DAO supplementation represents a targeted approach to address the underlying enzymatic deficiency in histamine intolerance. Oral DAO enzymes, derived from porcine kidney extracts, are typically administered as 0.3 mg or 10,000 HDU (histamine-degrading units) per dose, often 1-4 capsules taken 15-30 minutes before meals containing histamine.^[2] Small clinical studies involving 14-39 patients have demonstrated symptom improvements, including reduced headache severity and urticaria intensity, over 14-30 days of supplementation.^[1] For instance, a randomized double-blind trial in patients with episodic migraines associated with DAO deficiency reported significant reductions in headache frequency and duration.^[2] Mast cell stabilizers, such as cromolyn sodium, are employed to inhibit the degranulation of mast cells and subsequent histamine release, particularly in cases with overlapping mast cell activation features. Cromolyn sodium, available in oral form for gastrointestinal symptoms, has shown potential in preclinical models to mitigate histamine-mediated inflammation, though direct evidence in histamine intolerance remains limited to case series and extrapolations from allergic conditions.^[26] As an adjunct, vitamin C at doses of 500-1000 mg daily acts as a natural antihistamine by promoting histamine degradation and stabilizing mast cells, with studies indicating reduced serum histamine levels following administration.^[19]^[27] Probiotics may support gut health by fostering a microbiota composition that enhances endogenous DAO production and reduces histamine-producing bacteria. Strains like Lactiplantibacillus plantarum have been investigated for their role in modulating histamine metabolism, with preliminary evidence suggesting improvements in symptoms through restoration of intestinal barrier function.^[28] However, selection of low-histamine or histamine-degrading strains is crucial to avoid exacerbation.^[29] Despite these options, evidence for treatment efficacy is constrained by the scarcity of large-scale randomized controlled trials (RCTs), with most data derived from small observational studies or those focused on related conditions like migraines.^[1] Recent reviews highlight the need for more robust RCTs to clarify benefits beyond placebo responses, which can influence perceived symptom relief.^[2] Treatment should be individualized, with adjustments based on symptom monitoring; discontinuation is recommended if no improvement occurs after 4-6 weeks to prevent unnecessary exposure.^[1]

Dietary and Lifestyle Interventions

The cornerstone of non-pharmacological management for histamine intolerance is the low-histamine diet, which serves as the primary intervention to alleviate symptoms by limiting dietary histamine intake and avoiding foods that trigger its release or inhibit its breakdown. This diet emphasizes the exclusion of high-histamine foods such as aged cheeses, cured meats, fermented products like sauerkraut and yogurt, alcohol, and certain fruits including citrus varieties, while prioritizing fresh, unprocessed options like rice, freshly caught fish prepared immediately, and non-citrus fresh vegetables such as broccoli and leafy greens. Additionally, histamine liberators—foods that prompt mast cells to release endogenous histamine, such as bananas, tomatoes, strawberries, and chocolate—are typically restricted to prevent exacerbation of symptoms.^[2]^[30]^[31] Implementation of the low-histamine diet often follows a phased approach to balance symptom relief with nutritional sustainability. The initial elimination phase lasts approximately four weeks, during which high-histamine and liberator foods are strictly avoided to reduce overall histamine load and monitor symptom resolution. This is followed by a reintroduction phase, where suspected trigger foods are systematically tested in small amounts over one to two weeks to identify individual tolerances, allowing for a personalized long-term plan that minimizes unnecessary restrictions. Throughout these phases, meal timing strategies, such as consuming smaller, more frequent meals, can help prevent histamine peaks by supporting steady DAO activity.^[32]^[29]^[2] Nutritional guidance is essential to mitigate risks associated with the diet's restrictiveness, ensuring balanced intake to avoid deficiencies that could further impair histamine metabolism. For instance, vitamin B6, a cofactor in DAO synthesis, should be maintained through sources like fresh poultry or potatoes to support enzymatic function, while overall nutrient monitoring prevents shortfalls in vitamins and minerals. Dietary fiber from low-histamine sources, such as oats or carrots, promotes gut health, which is crucial since intestinal integrity influences DAO production and histamine degradation.^[33]^[2]^[29] Lifestyle modifications complement the dietary approach by addressing factors that influence histamine levels and DAO efficacy. Stress reduction techniques, such as mindfulness or yoga, are recommended because elevated cortisol from chronic stress can inhibit DAO activity, worsening symptoms. Regular moderate exercise enhances circulation and metabolic health without overexertion that might trigger histamine release, while ensuring 7-9 hours of quality sleep nightly supports hormonal balance and recovery processes. Supporting gut microbiota through adequate fiber intake further aids in maintaining a healthy digestive environment conducive to optimal DAO function.^[2]^[34]^[32] Long-term adherence to these interventions can yield substantial benefits, with clinical studies reporting symptom improvements ranging from 33% to 100% in patients who consistently follow the low-histamine diet, particularly when combined with lifestyle adjustments. Digital tools, such as symptom-tracking apps and food diary applications, facilitate monitoring and personalization, helping individuals maintain compliance over time. However, challenges persist, including social dining limitations and difficulties with sustained adherence due to the diet's demands, which can impact quality of life for many affected individuals.^[2]^[29]^[32]

Broader Context

Epidemiology

Histamine intolerance is estimated to affect 1-3% of the global population, though precise figures remain uncertain due to challenges in diagnosis and limited large-scale studies.^[2] Prevalence data primarily derive from clinical cohorts and self-reports, with variations observed across subgroups; for instance, diamine oxidase (DAO) deficiency, a key contributor, appears in up to 87% of migraine patients but only 8% of children with chronic abdominal pain.^[2] Demographically, the condition is more common in women, who comprise the majority of reported cases, potentially linked to estrogen influences on histamine metabolism.^[2] It is more commonly reported in adults than in children, where diagnosis is challenging, and shows geographic variations, such as higher rates in European populations possibly related to dietary patterns.^[2]^[1] Key risk factors include genetic polymorphisms in the DAO gene, with several known variants, including at least four common single nucleotide polymorphisms (SNPs), that impair histamine breakdown, alongside comorbidities like irritable bowel syndrome (IBS), where intestinal dysbiosis and reduced DAO activity often co-occur.^[1]^[35] Other contributors encompass pharmacological inhibition by certain drugs, alcohol consumption, and nutritional deficiencies in vitamins or minerals essential for DAO function.^[1] Epidemiological data are constrained by underreporting stemming from nonspecific symptoms and lack of standardized diagnostic criteria, with most estimates based on small European cohorts from 2020-2024 rather than global surveys. As of 2025, a meta-analysis estimated higher prevalence in certain subgroups, up to 31% for related amine intolerances, underscoring ongoing diagnostic challenges.^[2]^[1]^[36] Diagnoses have risen since the 2010s, likely reflecting heightened awareness, improved recognition in clinical settings, and a surge in research publications, with approximately 80% of studies appearing in the past decade as of 2020.^[2]

Research Directions and Controversies

Current research on histamine intolerance (HIT) emphasizes the development of more reliable biomarkers, such as enhanced diamine oxidase (DAO) assays, to better identify impaired histamine degradation. A 2023 population-based survey using radio-extraction assays for DAO activity found that while 44% of participants had levels below 10 U/mL, there was no direct correlation with HIT symptoms, highlighting the need for refined cut-off values and validation of enzyme activity over simple ELISA measurements.^[37] Recent randomized controlled trials (RCTs) on DAO supplements have shown modest efficacy.^[14] Metagenomic analyses have linked gut microbiome dysbiosis to HIT, revealing higher abundances of histamine-producing bacteria like Proteus and Enterobacteriaceae in affected individuals compared to controls, suggesting a role for microbial modulation in future interventions.^[11] Significant evidence gaps persist, particularly in standardized diagnostics, as no single biomarker—whether DAO levels, urinary histamine metabolites, or genetic variants—reliably confirms HIT, leading to reliance on subjective symptom tracking and elimination diets.^[38] Longitudinal studies are lacking, with calls for prospective cohorts to assess prevalence, natural history, and long-term outcomes beyond short-term dietary trials.^[39] Controversies surround HIT's validity as a distinct clinical entity, with a 2023 placebo-controlled histamine challenge trial in 59 suspected cases finding that only 15% reacted specifically to histamine, while 63% of symptoms were attributable to non-histamine factors like nocebo effects or unrelated sensitivities.^[40] Critics, including some allergists, argue it may represent misdiagnosis of conditions like irritable bowel syndrome (IBS) or mast cell activation syndrome (MCAS), and the American Academy of Allergy, Asthma & Immunology (AAAAI) has expressed skepticism regarding its recognition as a formal diagnosis due to inconsistent evidence.^[25] Future directions include exploring genetic therapies targeting DAO variants in the AOC1 gene, where pilot studies have identified single nucleotide variants in up to 79% of symptomatic individuals, potentially paving the way for gene-editing approaches to restore enzyme function.^[41] In 2025, expert panels have advocated for consensus guidelines to standardize diagnostic criteria and trial designs, addressing the current fragmentation in research protocols.^[42] Societally, HIT gained media attention in 2023 through celebrity endorsements, such as Olympic gymnast McKayla Maroney's public account of her diagnosis and symptom management, boosting awareness but also contributing to self-diagnosis trends; however, limited insurance coverage persists due to its contested status.^[43]

References

[1]
Histamine Intolerance: Symptoms, Diagnosis, and Beyond - PMC - NIH
Apr 19, 2024 · Histamine intolerance is a condition characterized by the accumulation of histamine to a point that exceeds the body's capacity to eliminate it.
[2]
Histamine Intolerance: The Current State of the Art - PMC - NIH
Histamine intolerance, also referred to as enteral histaminosis or sensitivity to dietary histamine, can be defined as a disorder arising from reduced histamine ...
[3]
Histamine and histamine intolerance - PubMed
Histamine intolerance results from a disequilibrium of accumulated histamine and the capacity for histamine degradation.Missing: early 1980-1990
[4]
Histamine Intolerance—The More We Know the Less We ... - MDPI
In older publications, this type of intolerance is designated by the expressions pseudoallergy, enteral histaminosis or histamine sensitivity. HIT is defined as ...
[5]
Histamine Intolerance: Causes, Symptoms & Treatment
Histamine intolerance (HIT) is a proposed condition caused by an inability to digest histamine in your diet, leading to gastrointestinal and allergy-like ...
[6]
Histamine Intolerance: A Real Condition or Misdiagnosed Food ...
Aug 27, 2025 · Histamine intolerance (HIT), also termed enteral histaminosis or dietary histamine sensitivity, is frequently cited as a potential explanation ...
[7]
Biochemistry, Histamine - StatPearls - NCBI Bookshelf - NIH
May 1, 2023 · Acute urticaria and angioedema are associated with sensitivity to allergens such as foods, drugs, latex, and other substances and is due to IgE- ...
[8]
Role of Histamine in Modulating the Immune Response and ...
Histamine shows a dichotomous nature, whereby it is able to promote inflammatory and regulatory responses that contribute to pathological processes, such as ...
[9]
Genetic DAO Deficiency and Lower Urinary Tract Symptoms
It is estimated that DAO deficiency affects 15% of the general population, according to clinical practice. It may have a genetic background. In this sense, the ...<|separator|>
[10]
Intestinal Dysbiosis in Patients with Histamine Intolerance - PMC - NIH
Apr 23, 2022 · An underlying cause of histamine intolerance is diamine oxidase (DAO) deficiency, which leads to defective homeostasis and a higher systemic ...Missing: 2020-2024 | Show results with:2020-2024
[11]
Diamine Oxidase Interactions with Anti-Inflammatory and Anti ...
Some pharmaceutical drugs, including proton pump inhibitors (PPIs) [28] and NSAIDs [29], have been reported to potentially inhibit DAO activity, which could ...Missing: antibiotics | Show results with:antibiotics
[12]
Advances in the Clinical Application of Histamine and Diamine ...
Dec 26, 2022 · Histamine-induced food intolerance used to be defined as an intolerance to red wine and the symptoms of allergy after ingestion of histamine- ...
[13]
Measurement of diamine oxidase (DAO) during low-histamine or ...
May 20, 2024 · ... (DAO) during low-histamine or ordinary diet in patients with histamine intolerance ... after oral provocation with liquid histamine. Allergy ...
[14]
1-methylhistamine as a potential biomarker of food histamine ...
Oct 11, 2022 · The aim of this study was to assess the urinary excretion of HA and 1-methylhistamine (MHA) in individuals diagnosed with histamine intolerance and in a ...Missing: elevated meal
[15]
Study Protocol for a Prospective, Unicentric, Double-Blind ... - NIH
Dec 25, 2024 · The dietary management of this food intolerance consists of the follow-up of a low-histamine diet, often combined with DAO supplementation. To ...Missing: elevated post-
[16]
An Overlooked Diagnosis of Recurrent Anaphylaxis-Like Symptoms
Mar 16, 2025 · Proper management of histamine intolerance can improve the individual's quality of life. Keywords: allergy and anaphylaxis, fish allergy, food- ...
[17]
https://pmc.ncbi.nlm.nih.gov/articles/PMC11998628/
[18]
Histamine and histamine intolerance - ScienceDirect.com
The diagnosis of allergy usually proves to be negative because histamine intolerance is a pseudoallergy. Keeping of a diet diary has proven useful in tracking ...
[19]
Serum diamine oxidase activity in patients with histamine intolerance
Nov 16, 2015 · We found that 10 out of 14 patients had serum DAO activity<10 U/mL, which was the threshold suggested as a cutoff for probable histamine intolerance.
[20]
Histamine, Plasma | Test Detail | Quest Diagnostics
Avoid taking allergy causing drugs, antihistamines, oral corticosteroids and ... 1 mL plasma collected in an EDTA (lavender-top) tube. Minimum Volume.
[21]
Mast cell activation syndrome: An up-to-date review of literature - PMC
Jun 9, 2024 · ... mast cells, namely histamine intolerance and hereditary alpha tryptasemia. A thorough physical examination, together with a thorough history ...
[22]
Histamine intolerance: fact or fiction?
Aug 28, 2023 · Histamine intolerance (HIT) is a disorder postulated to involve an increased sensitivity to dietary histamine.
[23]
Stabilizing histamine release in gut mast cells mitigates peripheral ...
Oct 7, 2023 · Therefore, we tested the effect of the mast cell stabilizer, cromolyn ... Histamine and histamine intolerance. Am J Clin Nutr. 2007;85:1185–96 ...
[24]
Intravenous vitamin C in the treatment of allergies: an interim ... - NIH
In a recent study investigating the acute effect of 7.5 g of iv vitamin C on the histamine levels in 89 patients with allergies or upper respiratory infections, ...
[25]
Potential Role of Probiotic Strain Lactiplantibacillus plantarum in ...
Jun 19, 2025 · The study investigates the probiotic Lactiplantibacillus plantarum LP115 and its effect on histamine metabolism.
[26]
The dietary treatment of histamine intolerance reduces ... - Frontiers
Oct 20, 2022 · The dietary treatment of histamine intolerance reduces the abundance of some histamine-secreting bacteria of the gut microbiota in histamine ...
[27]
Low-Histamine Diets: Is the Exclusion of Foods Justified by Their ...
Apr 21, 2021 · All low-histamine diets unanimously advised the elimination of many fermented foods and beverages (ie, dry-fermented sausages, cured cheese, wine and beer).Missing: sources | Show results with:sources
[28]
Histamine intolerance and dietary management: A complete review
Histamine intolerance and dietary management: A complete review. Visits. 49273 ... low histamine content) were found for the same food. This was the case ...
[29]
Evidence for Dietary Management of Histamine Intolerance - PMC
Sep 20, 2025 · A screening tool for food sensitivity fear in the histamine intolerance population has not been developed. The Nine-Item Avoidant/Restrictive ...Missing: elevated post-
[30]
Histamine, histamine intoxication and intolerance - Elsevier
This difference in skin prick test allows discriminating for histamine intolerance with sufficient sensitivity and specificity. Therapy of HIT. The most ...
[31]
Histamine and Psychiatric Disorders - MedCentral
May 10, 2023 · “Stress, via cortisol, calls your nervous system into action, and it can trigger histamine release, making symptoms worse,” Dr. Galle explained.
[32]
Intestinal Dysbiosis in Patients with Histamine Intolerance - MDPI
Apr 23, 2022 · The aim of this study was to characterize the composition of the intestinal microbiota of patients with histamine intolerance symptoms and compare it with that ...<|separator|>
[33]
The Use of DAO as a Marker for Histamine Intolerance - NIH
Jun 26, 2023 · According to World Allergy Organization, histamine intolerance (HIT) is classified as a non-allergic food hypersensitivity [1,2] and can be ...Missing: biochemical | Show results with:biochemical
[34]
Histamine intolerance: What current studies really show
Oct 8, 2025 · Placebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance. The Journal of Allergy and Clinical Immunology: In Practice ...Missing: directions | Show results with:directions
[35]
Study Protocol for a Prospective, Unicentric, Double-Blind ... - MDPI
A prospective, unicentric, double-blind, randomized, placebo-controlled clinical trial, involving 400 patients with histamine intolerance, will be conducted ...2. Materials And Methods · 2.1. Study Design · 2.1. 3. Dietary Intervention
[36]
Placebo-Controlled Histamine Challenge Disproves Suspicion of ...
Aug 28, 2023 · Placebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3724-3731 ...
[37]
Pilot Study on the Prevalence of Diamine Oxidase Gene Variants in ...
The study found that 79% of individuals with symptoms of histamine intolerance harbored one or more of the four SNVs associated with reduced DAO activity. No ...Missing: autosomal recessive
[38]
AI Medical Assessment | Hedfirst
... Diagnosis Found.. AI Analysis and Suggestions. Primary Hypothesis. Mast Cell Activation Syndrome (MCAS) with Histamine Intolerance. Statistically Most ...
[39]
Evidence for Dietary Management of Histamine Intolerance - MDPI
For example, there is a high variability on the histamine content of fermented foods depending on the quality of the raw material, the manufacturing process ...
[40]
McKayla Maroney talks health scare. What is histamine intolerance?
Oct 9, 2023 · Maroney was eventually diagnosed with something called “histamine intolerance,” and she's getting some relief and sleeping again.Missing: celebrity | Show results with:celebrity